Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week

Journal Scan / Research · October 11, 2021

High-Dose IL-2 and SAbR for Metastatic Renal Cell Carcinoma

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma
Clin. Cancer Res 2021 Sep 22;[EPub Ahead of Print], R Hannan, O Mohamad, A Diaz de Leon, S Manna, LM Pop, Z Zhang, S Mannala, A Christie, S Christley, N Monson, D Ishihara, EJ Hsu, C Ahn, P Kapur, M Chen, Y Arriaga, K Courtney, B Cantarel, EK Wakeland, YX Fu, I Pedrosa, L Cowell, T Wang, V Margulis, H Choy, RD Timmerman, J Brugarolas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading